Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission

详细信息    查看全文

• 作者：Tetsuya Eto (1)
  Ken Takase (1)
  Toshihiro Miyamoto (2)
  Yuju Ohno (3)
  Tomohiko Kamimura (4)
  Koji Nagafuji (5)
  Yasushi Takamatsu (6)
  Takanori Teshima (7)
  Hisashi Gondo (8)
  Shuichi Taniguchi (9)
  Koichi Akashi (2)
  Mine Harada (10)
  
• 关键词：Acute myelogenous leukemia ; First complete remission ; Postremission therapy ; Autologous peripheral blood stem cell transplantation ; G ; CSF combined conditioning regimen
• 刊名：International Journal of Hematology
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：98
• 期：2
• 页码：186-196
• 全文大小：385KB
• 参考文献：1. Seshadri T, Keating A. Is there a role for autotransplants in AML in first remission? Biol Blood Marrow Transpl. 2009;15:17-0. CrossRef
  2. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-3.
  3. D?hner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al.; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-4.
  4. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109:3658-6. CrossRef
  5. Gondo H, Harada M, Miyamoto T, Takenaka K, Tanimoto K, Mizuno S, et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transpl. 1997;20:821-. CrossRef
  6. Makino S, Harada M, Akashi K, Taniguchi S, Shibuya T, Inaba S, et al. A simplified method for cryopreservation of peripheral blood stem cells at ?0 degrees C without rate-controlled freezing. Bone Marrow Transpl. 1991;8:239-4.
  7. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-.
  8. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540-. CrossRef
  9. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065-1. CrossRef
  10. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-3. CrossRef
  11. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-6. CrossRef
  12. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet. 1998;351:700-. CrossRef
  13. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-3. CrossRef
  14. Breems DA, L?wenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol. 2007;44:259-6. CrossRef
  15. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60?years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol. 2005;128:59-5. CrossRef
  16. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T et al.; Hellenic Cooperative Group. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003;97:1721-1.
  17. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24:2480-. CrossRef
  18. Keating A, Kukreja M, Silva GT, Gupta V, Cutler C, Tallman MS, et al. Similar 5-year survival after peripheral blood autotransplants (AutoPB) versus HLA matched sibling myeloablative transplants (AlloBMT) for acute myeloid leukemia (AML) in first complete remission (CR1). Blood. 2008;112:2168. CrossRef
  19. Lemoli RM, D’Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, et al. BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)-retrospective study. Bone Marrow Transpl. 2009;45:640-. CrossRef
  20. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73:1272-.
  21. L?wenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P et al.; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-2.
  22. Takahashi S, Oshima Y, Okamoto S, Nishiwaki K, Nagayama H, Inoue T, et al. Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. Am J Hematol. 1998;57:303-. CrossRef
  23. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010;28:275-0.
  24. Gorin NC, Labopin M, Blaise D, Reiffers J, Meloni G, Michallet M et al.; Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol. 2009;27:3987-3.
  25. Miyamoto T, Nagafuji K, Harada M, Eto T, Fujisaki T, Kubota A, et al. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. Br J Haematol. 1995;91:132-. CrossRef
  26. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60?years with acute myelogenous leukemia. Biol Blood Marrow Transpl. 2006;12:466-1. CrossRef
  27. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA et al.; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904-1.
  28. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:3183-. CrossRef
  29. Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol. 2005;82:85-2. CrossRef
  30. Yoshimoto G, Nagafuji K, Miyamoto T, Kinukawa N, Takase K, Eto T, et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 2005;36:977-3. CrossRef
  31. Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-0?years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007;92:389-6. CrossRef
  32. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:523-6. CrossRef
  
• 作者单位：Tetsuya Eto (1)
  Ken Takase (1)
  Toshihiro Miyamoto (2)
  Yuju Ohno (3)
  Tomohiko Kamimura (4)
  Koji Nagafuji (5)
  Yasushi Takamatsu (6)
  Takanori Teshima (7)
  Hisashi Gondo (8)
  Shuichi Taniguchi (9)
  Koichi Akashi (2)
  Mine Harada (10)
  
  1. Department of Hematology, Hamanomachi Hospital, 3-5-27 Maizuru, Chuo-ku, Fukuoka, 810-8539, Japan
  2. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
  3. Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
  4. Department of Hematology, Harasanshin Hospital, Fukuoka, Japan
  5. Division of Hematology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
  6. Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, Fukuoka, Japan
  7. Center for Cellular Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
  8. Department of Internal Medicine, Koseikan Saga Prefecture Hospital, Saga, Japan
  9. Department of Hematology, Toranomon Hospital, Tokyo, Japan
  10. Department of Internal Medicine, Ohmuta National Hospital, Ohmuta, Japan
  

文摘

We retrospectively analyzed the outcomes of 81 patients with non-M3 acute myelogenous leukemia (AML) in first complete remission (CR1) who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (Auto-PBSCT) by the Fukuoka Blood and Marrow Transplantation Group between 1989 and 2005. Cytogenetically, 16 patients were defined as good risk, 56 as intermediate risk, and nine as poor risk, following the Southwest Oncology Group criteria. The pre-transplant conditioning regimen consisted of high-dose busulfan, etoposide, and cytarabine (BEA regimen), combined with priming by granulocyte colony-stimulating factor (G-CSF). Disease-free survival (DFS) and overall survival at 5?years were 64.0?% (95?% CI 52.5-3.4) and 66.4?% (95?% CI 54.9-5.6) after Auto-PBSCT at a median follow-up time of 103?months (range 3-40?months), respectively. Two patients died of transplant-related pulmonary complications 6?months after Auto-PBSCT without relapse. The 5-year DFS rates of patients in the genetically good-, intermediate-, and poor-risk groups were 80.8, 64.3, and 33.3?%, respectively, but there was no significant difference statistically among the risk groups (log-rank p?=?0.0579). These observations suggest that HDCT supported by Auto-PBSCT with the BEA regimen combined with G-CSF priming is a therapeutic option for postremission therapy of AML in CR1.